A Prospective Study of the Impact of <i>AGTR1</i> A1166C on the Effects of Candesartan in Patients with Heart Failure
Simon de Denus(Montreal Heart Institute), Serge Lepage, Mathieu Langlois(Montreal Heart Institute), Marie‐Claude Guertin, Anique Ducharme(Montreal Heart Institute), Marie‐Pierre Dubé(Montreal Heart Institute), Sylvie Provost(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Marie-Hélène Leblanc, Richard Sheppard(Jewish General Hospital), Michel White(Montreal Heart Institute), Jean‐Claude Tardif(Montreal Heart Institute), Ian Mongrain(Montreal Heart Institute), Nadia Giannetti(Inserm), Jacques Turgeon(Unknown), Michael Phillips(The University of Western Australia), Valérie Normand(Montreal Heart Institute), Thao Huynh(AstraZeneca (United Kingdom)), Jean‐Lucien Rouleau(Montreal Heart Institute), Asmaa Mansour(Montreal Heart Institute), René Fouodjio(Montreal Heart Institute), Joël Lavoie(Montreal Heart Institute)
Cited by 17
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k